DK2001496T3 - Anvendelse af gelsolin til diagnosticering og behandling af inflammationssygdomme - Google Patents
Anvendelse af gelsolin til diagnosticering og behandling af inflammationssygdomme Download PDFInfo
- Publication number
- DK2001496T3 DK2001496T3 DK07753102.8T DK07753102T DK2001496T3 DK 2001496 T3 DK2001496 T3 DK 2001496T3 DK 07753102 T DK07753102 T DK 07753102T DK 2001496 T3 DK2001496 T3 DK 2001496T3
- Authority
- DK
- Denmark
- Prior art keywords
- gelsolin
- level
- risk
- subject
- disease
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4703—Regulators; Modulating activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4712—Muscle proteins, e.g. myosin, actin, protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
- G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
- G01N2800/104—Lupus erythematosus [SLE]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/24—Immunology or allergic disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Rehabilitation Therapy (AREA)
- Physical Education & Sports Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Neurology (AREA)
Claims (12)
1. Fremgangsmåde til karakterisering af en rask persons risikoprofil for at udvikle en fremtidig inflammationssygdom, der omfatter: sammenligning af et niveau af gelsolin i en kropsvæske (for eksempel blod, plasma, serum, urin, synovialvæske eller alveolevæske) eller et væv (for eksempel fra et led, mave-tarm-kanalen, thyreoidea, binyrerne, et blodkar, lunge, nyre, hjerte, hud, øje, hjerne, pankreas, lever, nerve eller muskel) opnået fra personen med en forudbestemt værdi (fortrinsvis ca. 250 mg/1 plasma eller mindre) og karakterisering af den raske persons risikoprofil for at udvikle en inflammationssygdom baseret på niveauet af gelsolin sammenlignet med den forudbestemte værdi, hvor et niveau af gelsolin på eller under det forudbestemte niveau er tegn på, at personen har forhøjet risiko for at udvikle inflammationssygdommen, og hvor et niveau af gelsolin på eller over det forudbestemte niveau er tegn på, at personen ikke har forhøjet risiko for at udvikle inflammationssygdommen, hvor personen ikke har tegn eller symptomer på en infektion, sepsis eller en aktin-relateret lidelse.
2. Fremgangsmåde ifølge krav 1, hvor inflammationssygdommen er arthritis, rheumatoid arthritis, astma, inflammatorisk tarm sygdom (Crohns sygdom eller ulcerativ colitis), kronisk obstruktiv lungesygdom (KOL), allergisk rhinitis, vasculitis (polyarteritis nodosa, temporal arteritis, Wegeners granulomatose, Takayasus arteritis eller Behcets syndrom), inflammatorsk neuropati, psoriasis, systemisk lupus erythematosis (SLE), kronisk thyreoiditis, Hashimotos thyreoiditis, Addisons sygdom, polymyalgia rheumatica, Sjogrens syndrom eller Churg-Strauss' syndrom.
3. Fremgangsmåde ifølge krav 1, der yderligere omfatter udførelse af en eller flere tests til evaluering af inflammationssygdommen, fortrinsvis hvor testen er måling af et niveau af en inflammationsmarkør hos personen, hvor inflammationsmarkøren for eksempel er CRP, opløseligt intercellulært adhæsionsmolekyle (sICAM-1), ICAM 3, BL-CAM, LFA-2, VCAM-I, NCAM, PECAM, fibrinogen, serumamyloid A (SAA), lipoprotein-associeret phospholipase A2 (LpPIA2), sCD40-ligand (sCD40L), myeloperoxidase, interleukin-6 (IL-6) eller interleukin-8 (IL-8).
4. Fremgangsmåde til karakterisering en rask persons risikoprofil for at udvikle en fremtidig inflammationssygdom, der omfatter: sammenligning af niveauet af gelsolin i en prøve opnået fra en person med en første forudbestemt værdi (fortrinsvis ca. 250 mg/1 plasma eller mindre) til bestemmelse af en første risikoværdi, sammenligning af niveauet af en anden inflammationsmarkør i en prøve opnået fra en person med en anden forudbestemt værdi til bestemmelse af en anden risikoværdi og karakterisering af personens risikoprofil for at udvikle inflammationssygdommen baseret på kombinationen af den første risikoværdi og den anden risikoværdi, hvor kombinationen af den første risikoværdi og anden risikoværdi tilvejebringer en tredje risikoværdi, der er forskellig fra den første og anden risikoværdi, hvor personen ikke har tegn eller symptomer på en infektion, sepsis eller en aktin-relateret lidelse.
5. Fremgangsmåde ifølge krav 4, hvor den første forudbestemte værdi er et antal forudbestemte intervaller for gelsolin-niveauet, hvor et af intervallerne er under ca. 250 mg/1 plasma, og et andet af intervallerne er over ca. 250 mg/1 plasma, og hvor sammenligningstrinet omfatter bestemmelse af, i hvilket af antallet af forudbestemte intervaller for gelsolin-niveauet personens gelsolin-niveau falder.
6. Gelsolin eventuelt i kombination med et andet middel til behandling af en inflammationssygdom til anvendelse i en fremgangsmåde til behandling af en person, der har risiko for at udvikle en inflammationssygdom, som fortrinsvis ellers er fri for indikationer, der indicerer behandling med gelsolin, fortrinsvis hvor gelsolinen er plasmagelsolin (pGSN), cytoplasmatisk gelsolin (cGSN), advillin, villin, capG, flightless-proteiner, fragmin, severin, adseverin, protovillin eller supervillin.
7. Gelsolin ifølge krav 6, hvor inflammationssygdommen er arthritis, rheumatoid arthritis, astma, inflammatorisk tarmsygdom (Crohns sygdom eller ulcerativ colitis), kronisk obstruktiv lungesygdom (KOL), allergisk rhinitis, vasculitis (polyarteritis nodosa, temporal arteritis, Wegeners granulomatose, Takayasus arteritis eller Behcets syndrom), inflammatorsk neuropati, psoriasis, systemisk lupus erythematosis (SLE), kronisk thyreoiditis, Hashimotos thyreoiditis, Addisons sygdom, polymyalgia rheumatica, Sjogrens syndrom eller Churg-Strauss' syndrom.
8. Gelsolin ifølge krav 6, hvor det andet middel til behandling af inflammationssygdommen er alclofenac, alclometasondipropionat, algestonacetonid, alfa-amylase, amcinafal, amcinafid, amfenacnatrium, amiprilosehydrochlorid, anakinra, anirolac, anitrazafen, apazon, balsalaziddinatrium, bendazac, benoxaprofen, benzydaminhydrochlorid, bromelainer, broperamol, budesonid, carprofen, cicloprofen, cintazon, cliprofen, clobetasol-propionat, clobetasonbutyrat, clopirac, cloticasonpropionat, cormethason-acetat, cortodoxon, cyclooxygenase-2 (COX-2)-hæmmer, deflazacort, desonid, desoximetason, dexamethasondipropionat, diclofenackalium, diclofenacnatrium, diflorasondiacetat, diflumidonnatrium, diflunisal, difluprednat, diftalon, dimethylsulfoxid, drocinonid, endryson, enlimomab, enolicamnatrium, epirizol, etodolac, etofenamat, felbinac, fenamol, fenbufen, fenclofenac, fenclorac, fendosal, fenpipalon, fentiazac, flazalon, fluazacort, flufenamsyre, flumizol, flunisolidacetat, flunixin, flunixinmeglumin, fluocortinbutyl, fluorometholonacetat, fluquazon, flurbiprofen, fluretofen, fluticasonpropionat, furaprofen, furobufen, halcinonid, halobetasol propionat, halopredonacetat, ibufenac, ibuprofen, ibuprofen aluminum, ibuprofen piconol, ilonidap, indomethacin, indomethacinnatrium, indoprofen, indoxol, intrazol, isoflupredonacetat, isoxepac, isoxicam, ketoprofen, lofemizolhydrochlorid, lornoxicam, loteprednoletabonat, meclofenamatnatrium, meclofenamsyre, meclorisondibutyrat, mefenamsyre, mesalamin, meseclazon, methylprednisolonsuleptanat, morniflumat, nabumeton, naproxen, naproxennatrium, naproxol, nimazon, olsalazinnatrium, orgotein, orpanoxin, oxaprozin, oxyphenbutazon, paranylinhydrochlorid, pentosanpolysulfatnatrium, phenbutazon-natriumglycerat, pirfenidon, piroxicam, piroxicamcinnamat, piroxicamolamin, pirprofen, prednazat, prifelon, prodolinsyre, proquazon, proxazol, proxazolcitrat, rimexolon, romazarit, salcolex, salnacedin, salsalat, sanguinariumchlorid, seclazon, sermetacin, sudoxicam, sulindac, suprofen, talmetacin, talniflumat, talosalat, tebufelon, tenidap, tenidapnatrium, tenoxicam, tesicam, tesimid, tetrydamin, tiopinac, tixocortolpivalat, tolmetin, tolmetinnatrium, triclonid, triflumidat, zidometacin eller zomepiracnatrium.
9. Gelsolin ifølge krav 6, der yderligere omfatter administrering af et andet middel til behandling af rheumatoid arthritis .
10. Gelsolin ifølge krav 9, hvor det andet middel til behandling af rheumatoid arthritis er hydroxychloroquin (Plaquenil), chloroquin (Aralen), methotrexat, sulfasalazin (Azulfidine), leflunomid (Arava), azathioprin (Imuran), penicillamin (Cuprimine eller Depen), guldsalte (Ridaura eller Aurolate), minocyclin (Dynacin eller Minocin), cyclosporin (Neoral eller Sandimmune) cyclophosphamid (Cytoxan eller Neosar), etanercept (Enbrel), infliximab (Remicade), anakinra (Kineret) eller adalimumab (Humira).
11. Gelsolin eventuelt i kombination med et andet middel til anvendelse i en fremgangsmåde til behandling af en person, der har risiko for at udvikle en inflammationssygdom, hvor det er kendt, at gelsolin er under normalniveau; i en effektiv mængde til at reducere risikoen hos personen for at udvikle inflammationssygdommen.
12. Gelsolin eventuelt i kombination med et andet middel til anvendelse i en fremgangsmåde til behandling af en person, der har risiko for at udvikle en inflammationssygdom, hvor det er kendt, at gelsolin er under normalniveau; i en effektiv mængde til at hæve niveauet af gelsolin hos personen over en forudbestemt værdi.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US78250806P | 2006-03-15 | 2006-03-15 | |
PCT/US2007/006451 WO2007109056A2 (en) | 2006-03-15 | 2007-03-15 | Use of gelsolin to diagnose and treat inflammatory diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2001496T3 true DK2001496T3 (da) | 2017-09-18 |
Family
ID=38522935
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK17173554.1T DK3279663T3 (da) | 2006-03-15 | 2007-03-15 | Anvendelse af gelsolin til diagnosticering og behandling af inflammationssygdomme |
DK07753102.8T DK2001496T3 (da) | 2006-03-15 | 2007-03-15 | Anvendelse af gelsolin til diagnosticering og behandling af inflammationssygdomme |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK17173554.1T DK3279663T3 (da) | 2006-03-15 | 2007-03-15 | Anvendelse af gelsolin til diagnosticering og behandling af inflammationssygdomme |
Country Status (14)
Country | Link |
---|---|
US (3) | US8198094B2 (da) |
EP (2) | EP3279663B1 (da) |
JP (5) | JP5322917B2 (da) |
KR (2) | KR20140091048A (da) |
CN (2) | CN107085113B (da) |
AU (1) | AU2007227613A1 (da) |
CA (1) | CA2680413C (da) |
DK (2) | DK3279663T3 (da) |
ES (2) | ES2641879T3 (da) |
HK (1) | HK1250781A1 (da) |
HU (2) | HUE056086T2 (da) |
PL (2) | PL3279663T3 (da) |
PT (2) | PT3279663T (da) |
WO (1) | WO2007109056A2 (da) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9408891B2 (en) | 2003-11-12 | 2016-08-09 | The Trustees Of The University Of Pennsylvania | Methods of using gelsolin to treat or prevent bacterial sepsis |
PL1694342T3 (pl) * | 2003-11-12 | 2021-07-05 | Trustees Of The University Of Pennsylvania | Sposoby zastosowania gelsoliny do leczenia lub zapobiegania posocznicy bakteryjnej |
WO2005112970A2 (en) * | 2004-05-12 | 2005-12-01 | The Brigham And Women's Hospital, Inc. | Use of gelsolin to treat infections |
JP4348631B2 (ja) * | 2005-03-29 | 2009-10-21 | セイコーエプソン株式会社 | 半導体素子の製造方法 |
PL3279663T3 (pl) | 2006-03-15 | 2022-01-10 | The Brigham And Women's Hospital, Inc. | Zastosowanie gelsoliny do diagnozowania i leczenia chorób zapalnych |
US8440622B2 (en) * | 2006-03-15 | 2013-05-14 | The Brigham And Women's Hospital, Inc. | Use of gelsolin to treat multiple sclerosis and to diagnose neurologic disease (stossel) |
US7526337B2 (en) * | 2006-06-06 | 2009-04-28 | Cardiac Pacemakers, Inc. | Method and device for lymphatic system monitoring |
US20070282376A1 (en) | 2006-06-06 | 2007-12-06 | Shuros Allan C | Method and apparatus for neural stimulation via the lymphatic system |
US7734341B2 (en) | 2006-06-06 | 2010-06-08 | Cardiac Pacemakers, Inc. | Method and apparatus for gastrointestinal stimulation via the lymphatic system |
US8905999B2 (en) | 2006-09-01 | 2014-12-09 | Cardiac Pacemakers, Inc. | Method and apparatus for endolymphatic drug delivery |
JP2010537625A (ja) * | 2007-08-15 | 2010-12-09 | マウントゲイト グループ リミテッド | ゲルゾリン結合剤組成物およびその使用 |
DK2250280T3 (da) * | 2008-01-25 | 2015-03-09 | Gen Hospital Corp | Terapeutiske anvendelser af gelsolin ved nyreinsufficiens |
EP2311823A1 (en) * | 2009-10-15 | 2011-04-20 | AC Immune S.A. | 2,6-Diaminopyridine compounds for treating diseases associated with amyloid proteins or for treating ocular diseases |
DE102010026500A1 (de) * | 2010-07-07 | 2012-01-12 | Arthrogen Gmbh | Verfahren zur Herstellung von autologen Proteinen |
NZ703532A (en) * | 2012-07-05 | 2018-02-23 | Taiwan Liposome Co Ltd | Methods of treating arthritis |
KR101416954B1 (ko) * | 2012-09-12 | 2014-07-16 | 한양대학교 산학협력단 | 조혈세포 분화 유도 방법 |
EP3118325B1 (en) * | 2014-03-11 | 2019-07-24 | IUCF-HYU (Industry-University Cooperation Foundation Hanyang University) | Blood disease diagnosis |
WO2016033187A1 (en) * | 2014-08-26 | 2016-03-03 | The Brigham And Women's Hospital, Inc. | Use of gelsolin in the treatment and diagnosis of sickle cell disease |
WO2016040987A1 (en) * | 2014-09-15 | 2016-03-24 | Abregen Pty Ltd | Treating and/or preventing psoriasis |
IT201700083044A1 (it) * | 2017-07-20 | 2019-01-20 | Laura Stronati | “uso della gelsolina come marcatore diagnostico e prognostico delle malattie infiammatorie intestinali” |
US20230357388A1 (en) * | 2020-09-25 | 2023-11-09 | The Francis Crick Institute Limited | Immunotherapy |
CN112630430B (zh) * | 2020-11-16 | 2021-08-27 | 北京美联泰科生物技术有限公司 | 一种定量检测uchl-1的试剂盒及其应用 |
Family Cites Families (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5071773A (en) | 1986-10-24 | 1991-12-10 | The Salk Institute For Biological Studies | Hormone receptor-related bioassays |
CA2016227A1 (en) | 1989-05-18 | 1990-11-18 | Xandra O. Breakefield | Genetic diagnosis of torsion dystonia |
ES2124702T3 (es) | 1990-04-11 | 1999-02-16 | Brigham & Womens Hospital | Usos terapeuticos de compuestos que se unen a actina. |
US5464817A (en) | 1990-04-11 | 1995-11-07 | Brigham And Women's Hospital | Method for reducing the viscosity of pathological mucoid airway contents in the respiratory tract comprising administering actin-binding compounds with or without DNASE I |
CA2063593A1 (en) | 1990-05-04 | 1991-11-05 | R. Blake Pepinsky | Multimeric gelsolin fusion constructs |
US5571511A (en) | 1990-10-22 | 1996-11-05 | The U.S. Government | Broadly reactive opsonic antibodies that react with common staphylococcal antigens |
NZ241954A (en) | 1991-03-15 | 1994-01-26 | Amgen Inc | Compositions of g-csf for pulmonary administration. |
US5360350A (en) | 1991-08-23 | 1994-11-01 | The Whitaker Corporation | Sealant compositions and sealed electrical connectors |
WO1994003601A2 (en) | 1992-08-03 | 1994-02-17 | New York University | Cloning, expression and uses for neurocan as a chondroitin sulfate proteoglycan |
US5691160A (en) | 1992-08-14 | 1997-11-25 | Biogen, Inc. | Effects of actin filaments of fibrin clot structure and lysis |
JPH08506001A (ja) | 1992-10-01 | 1996-07-02 | ザ ゼネラル ホスピタル コーポレーション | 腫瘍サプレッサー遺伝子の機能検査 |
US5604260A (en) | 1992-12-11 | 1997-02-18 | Merck Frosst Canada Inc. | 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2 |
US5543297A (en) | 1992-12-22 | 1996-08-06 | Merck Frosst Canada, Inc. | Human cyclooxygenase-2 cDNA and assays for evaluating cyclooxygenase-2 activity |
US5830436A (en) | 1993-03-30 | 1998-11-03 | Duke University | Method of mucociliary clearance in cystic fibrosis patients using alkylaryl polyether alcohol polymers |
GB9602877D0 (en) | 1996-02-13 | 1996-04-10 | Merck Frosst Canada Inc | 3,4-Diaryl-2-hydroxy-2,5- dihydrofurans as prodrugs to cox-2 inhibitors |
US5474995A (en) | 1993-06-24 | 1995-12-12 | Merck Frosst Canada, Inc. | Phenyl heterocycles as cox-2 inhibitors |
US5593964A (en) | 1993-10-07 | 1997-01-14 | The George Washington University Medical Center | Method of treating septic shock by preventing actin polymerization |
JP3914272B2 (ja) | 1993-12-28 | 2007-05-16 | 中外製薬株式会社 | アドゼベリンをコードする遺伝子 |
AU1269495A (en) | 1994-01-10 | 1995-08-01 | Merck Frosst Canada Inc. | Phenyl heterocycles as cox-2 inhibitors |
JPH09510212A (ja) | 1994-03-11 | 1997-10-14 | メルク エンド カンパニー インコーポレーテッド | 肺疾患を処置するための組成物 |
US5451569A (en) | 1994-04-19 | 1995-09-19 | Hong Kong University Of Science And Technology R & D Corporation Limited | Pulmonary drug delivery system |
US5521213A (en) | 1994-08-29 | 1996-05-28 | Merck Frosst Canada, Inc. | Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2 |
WO1996013483A1 (en) | 1994-10-27 | 1996-05-09 | Merck Frosst Canada Inc. | Stilbene derivatives useful as cyclooxygenase-2 inhibitors |
US5552422A (en) | 1995-01-11 | 1996-09-03 | Merck Frosst Canada, Inc. | Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents |
US5563153A (en) | 1995-02-22 | 1996-10-08 | University Of Kansas Medical Center | Sterile topical anesthetic gel |
US5846743A (en) | 1995-02-22 | 1998-12-08 | Brigham And Women's Hospital, Inc. | Polyphoshoinositide binding peptides for intracellular drug delivery |
EP0815134B1 (en) | 1995-03-14 | 2002-06-05 | Praecis Pharmaceuticals Incorporated | Modulators of amyloid aggregation |
US5774303A (en) | 1995-03-24 | 1998-06-30 | Stormedia, Inc. | Sputter induced micro-texturing enhancement for magnetic head structures |
US5691374A (en) | 1995-05-18 | 1997-11-25 | Merck Frosst Canada Inc. | Diaryl-5-oxygenated-2-(5H) -furanones as COX-2 inhibitors |
US5804427A (en) | 1995-05-19 | 1998-09-08 | University Of Massachusetts | Cytokine-, stress-, and oncoprotein-activated human protein kinase kinases |
US5639780A (en) | 1995-05-22 | 1997-06-17 | Merck Frosst Canada, Inc. | N-benzyl indol-3-yl butanoic acid derivatives as cyclooxygenase inhibitors |
US5604253A (en) | 1995-05-22 | 1997-02-18 | Merck Frosst Canada, Inc. | N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase inhibitors |
US5643933A (en) | 1995-06-02 | 1997-07-01 | G. D. Searle & Co. | Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors |
US5925529A (en) | 1995-06-07 | 1999-07-20 | The Regents Of The University Of California | Method for discovery of peptide agonists |
US5569588A (en) | 1995-08-09 | 1996-10-29 | The Regents Of The University Of California | Methods for drug screening |
US5750353A (en) | 1995-12-11 | 1998-05-12 | New England Medical Center Hospitals, Inc. | Assay for non-peptide agonists to peptide hormone receptors |
US5789413A (en) | 1996-02-01 | 1998-08-04 | Merck Frosst Canada, Inc. | Alkylated styrenes as prodrugs to COX-2 inhibitors |
US5733909A (en) | 1996-02-01 | 1998-03-31 | Merck Frosst Canada, Inc. | Diphenyl stilbenes as prodrugs to COX-2 inhibitors |
GB9607503D0 (en) | 1996-04-11 | 1996-06-12 | Merck Frosst Canada Inc | Bisaryl cyclobutenes derivatives as cyclooxygenase inhibitors |
US5922742A (en) | 1996-04-23 | 1999-07-13 | Merck Frosst Canada | Pyridinyl-2-cyclopenten-1-ones as selective cyclooxygenase-2 inhibitors |
US5677318A (en) | 1996-07-11 | 1997-10-14 | Merck Frosst Canada, Inc. | Diphenyl-1,2-3-thiadiazoles as anti-inflammatory agents |
US5861419A (en) | 1996-07-18 | 1999-01-19 | Merck Frosst Canad, Inc. | Substituted pyridines as selective cyclooxygenase-2 inhibitors |
AU3817497A (en) | 1996-07-30 | 1998-02-20 | Biogen, Inc. | Production of recombinant plasma gelsolin containing a disulfide bond |
CA2274002A1 (en) | 1996-12-04 | 1998-06-11 | The Victoria University Of Manchester | Wound healing and treatment of fibrosis |
PT1493439E (pt) * | 1997-04-02 | 2012-01-10 | Brigham & Womens Hospital | Meio de avaliação do perfil de risco de um indivíduo para uma doença aterosclerótica |
AU3395900A (en) | 1999-03-12 | 2000-10-04 | Human Genome Sciences, Inc. | Human lung cancer associated gene sequences and polypeptides |
ES2299436T3 (es) * | 1999-10-06 | 2008-06-01 | ABBOTT GMBH & CO. KG | Composicion que comprende un inhibidor de tnf-alfa y un antagonista de receptor de integrina alfavbeta3. |
AU2002225219A1 (en) | 2001-01-26 | 2002-08-06 | Oxford Glycosciences (Uk) Ltd | Diagnosis and treatment of multiple sclerosis |
MXPA03007878A (es) | 2001-03-02 | 2004-07-08 | Medimmune Inc | Metodos de prevencion o tratamiento de alteraciones inflamatorias o autoinmunes mediante la administracion de los antagonistas alfav, beta3 de integrina. |
EP1249244A1 (en) | 2001-04-13 | 2002-10-16 | Universiteit Gent | Therapeutic compositions for the treatment of a disease modulated by the G-actin / F-actin equilibrium, especially a respiratory tract disease |
NZ530764A (en) * | 2001-07-09 | 2008-07-31 | Combinatorx Inc | Composition comprising a tricyclic antidepressant and a corticosteroid administered simutaneously or within 14 days for treatment of inflammatory disorders |
CA2458677A1 (en) * | 2001-08-30 | 2003-03-13 | Praecis Pharmaceuticals Incorporated | Methods and compositions for treating inflammatory disorders |
US20080051348A1 (en) | 2002-02-06 | 2008-02-28 | Regenerx Biopharmaceuticals, Inc. | Treatment of infections and other disorders |
US20060089310A1 (en) | 2002-02-06 | 2006-04-27 | Regenerx Biopharmaceuticals, Inc. | Treatment of infections and other disorders |
WO2003088811A2 (en) | 2002-04-16 | 2003-10-30 | The Brigham And Women's Hospital, Inc. | Gelsolin as a prognostic marker of artherosclerotic diseases |
AU2003253014A1 (en) | 2002-06-21 | 2004-01-06 | Innogenetics N.V. | Method for the diagnosis and differential diagnosis of neurological diseases |
AU2003289716A1 (en) | 2002-09-12 | 2004-04-30 | Incyte Corporation | Molecules for diagnostics and therapeutics |
CA2516335A1 (en) | 2003-02-21 | 2004-09-02 | Medvet Science Pty. Ltd. | A method of diagnosis and treatment |
CA2527916A1 (en) * | 2003-03-14 | 2004-09-30 | Aaron B. Kantor | Biological markers for diagnosing rheumatoid arthritis |
GB0327723D0 (en) | 2003-09-15 | 2003-12-31 | Vectura Ltd | Pharmaceutical compositions |
US9408891B2 (en) * | 2003-11-12 | 2016-08-09 | The Trustees Of The University Of Pennsylvania | Methods of using gelsolin to treat or prevent bacterial sepsis |
PL1694342T3 (pl) | 2003-11-12 | 2021-07-05 | Trustees Of The University Of Pennsylvania | Sposoby zastosowania gelsoliny do leczenia lub zapobiegania posocznicy bakteryjnej |
CA2550833A1 (en) | 2003-12-22 | 2005-07-14 | Regenerx Biopharmaceuticals, Inc. | Method of treating or preventing biological or immunological responses to a reactive chemical or biological or toxic agent |
EP1721163B1 (en) | 2004-02-27 | 2015-04-29 | Roche Diagnostics GmbH | Method of assessing rheumatoid arthritis by measuring rheumatoid factor and interleukin-6 |
WO2005112970A2 (en) | 2004-05-12 | 2005-12-01 | The Brigham And Women's Hospital, Inc. | Use of gelsolin to treat infections |
KR20070029733A (ko) | 2004-06-04 | 2007-03-14 | 제넨테크, 인크. | 다발성 경화증의 치료 방법 |
US20100062471A1 (en) | 2005-09-29 | 2010-03-11 | Ppd Biomarker Discovery Sciences Llc | Biomarkers for Multiple Sclerosis and Methods of Use Thereof |
US8440622B2 (en) | 2006-03-15 | 2013-05-14 | The Brigham And Women's Hospital, Inc. | Use of gelsolin to treat multiple sclerosis and to diagnose neurologic disease (stossel) |
PL3279663T3 (pl) | 2006-03-15 | 2022-01-10 | The Brigham And Women's Hospital, Inc. | Zastosowanie gelsoliny do diagnozowania i leczenia chorób zapalnych |
DK2250280T3 (da) | 2008-01-25 | 2015-03-09 | Gen Hospital Corp | Terapeutiske anvendelser af gelsolin ved nyreinsufficiens |
KR101568323B1 (ko) | 2014-01-08 | 2015-11-12 | 한국원자력의학원 | 겔솔린을 유효성분으로 포함하는 수지상세포 분화 유도용 조성물 및 이의 분화 유도방법 |
WO2016033187A1 (en) | 2014-08-26 | 2016-03-03 | The Brigham And Women's Hospital, Inc. | Use of gelsolin in the treatment and diagnosis of sickle cell disease |
-
2007
- 2007-03-15 PL PL17173554T patent/PL3279663T3/pl unknown
- 2007-03-15 JP JP2009500462A patent/JP5322917B2/ja active Active
- 2007-03-15 DK DK17173554.1T patent/DK3279663T3/da active
- 2007-03-15 ES ES07753102.8T patent/ES2641879T3/es active Active
- 2007-03-15 KR KR1020147015554A patent/KR20140091048A/ko not_active Application Discontinuation
- 2007-03-15 HU HUE17173554A patent/HUE056086T2/hu unknown
- 2007-03-15 AU AU2007227613A patent/AU2007227613A1/en not_active Abandoned
- 2007-03-15 PT PT171735541T patent/PT3279663T/pt unknown
- 2007-03-15 PT PT77531028T patent/PT2001496T/pt unknown
- 2007-03-15 PL PL07753102T patent/PL2001496T3/pl unknown
- 2007-03-15 CN CN201610875666.0A patent/CN107085113B/zh active Active
- 2007-03-15 US US12/225,128 patent/US8198094B2/en active Active
- 2007-03-15 CN CNA2007800175589A patent/CN101443030A/zh active Pending
- 2007-03-15 KR KR1020087025043A patent/KR101556790B1/ko active IP Right Grant
- 2007-03-15 HU HUE07753102A patent/HUE035884T2/en unknown
- 2007-03-15 DK DK07753102.8T patent/DK2001496T3/da active
- 2007-03-15 EP EP17173554.1A patent/EP3279663B1/en active Active
- 2007-03-15 ES ES17173554T patent/ES2895078T3/es active Active
- 2007-03-15 CA CA2680413A patent/CA2680413C/en active Active
- 2007-03-15 WO PCT/US2007/006451 patent/WO2007109056A2/en active Application Filing
- 2007-03-15 EP EP07753102.8A patent/EP2001496B1/en active Active
-
2011
- 2011-12-09 JP JP2011270249A patent/JP2012083359A/ja not_active Withdrawn
-
2012
- 2012-04-25 US US13/455,878 patent/US9316639B2/en active Active
-
2014
- 2014-03-31 JP JP2014071355A patent/JP2014122924A/ja not_active Withdrawn
-
2015
- 2015-07-09 JP JP2015137491A patent/JP6198777B2/ja active Active
-
2016
- 2016-04-18 US US15/131,465 patent/US10238715B2/en active Active
-
2017
- 2017-05-17 JP JP2017098198A patent/JP6568144B2/ja active Active
-
2018
- 2018-08-07 HK HK18110130.0A patent/HK1250781A1/zh unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10238715B2 (en) | Methods for treating or reducing the risk of arthritis in a subject by administering gelsolin | |
US10272136B2 (en) | Diagnostic and therapeutic uses of gelsolin in renal failure | |
DK2002258T3 (da) | Anvendelse af gelsolin til behandling af multipel sklerose og diagnosticering af neurologiske sygdomme | |
WO2016033187A1 (en) | Use of gelsolin in the treatment and diagnosis of sickle cell disease | |
AU2013202205C1 (en) | Use of Gelsolin to Diagnose and Treat Inflammatory Disease | |
JP6158825B2 (ja) | テネイシンcおよび関節リウマチにおけるその使用 |